Pfizer Off-Label Marketing Suit Pushed Toward Dismissal

By Greg Ryan (April 25, 2012, 5:56 PM EDT) -- A Texas federal magistrate judge on Monday called for the dismissal of a Blue Cross Blue Shield operator's suit against Pfizer Inc. over its alleged off-label marketing of antipsychotic drug Geodon and antibiotic Zyvox.

Health Care Service Corp.'s amended complaint was defective in the same ways as its original complaint, U.S. Magistrate Judge Caroline M. Craven said: The health insurance provider did not adequately allege Pfizer's supposed misrepresentations caused it economic injury or caused doctors to prescribe the drugs for off-label use when they otherwise would not have.

HCSC seeks damages under the Racketeer Influenced and Corrupt Organizations Act, saying it...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!